Exclusive Summary

• The patent has long expired, presenting no IP barriers and allowing for rapid global market entry via the Distribution model.
• The dispersible capsule formulation (0.15g) acts quickly and improves patient compliance, offering a strong differentiated retail selling point over standard tablets.
• As a classic antibiotic for respiratory infections and Mycoplasma pneumonia, the hundreds of millions of global cases annually guarantee persistent and massive market demand.
• Backed by China's integrated API-to-finished-dosage supply chain, the product offers significant cost advantages, ensuring high profit margins for overseas distributors.